TABLE 7.

Summary of placebo-controlled clinical trials for secondary prevention of CVD

StudyConditionSerologic inclusion criteriaNo.InterventionaOutcomeResult (treatment vs placebo)
Gupta et al. (44)Post-MIMIF IgG ≥ 6460Azithromycin, 500 mg/day × 3 days, 500 mg/days × 6 daysAny coronary ischemic event8% vs. 25% (P = 0.03) at 18 mo
Gurfinkel et al. (47)Unstable anginaNone202Roxithromycin, 150 mg bid × 30 daysRecurrent CVD (triple end point)7% vs. 15% (P = 0.26) at 180 days
Muhlestein et al. (96)CAD (prior MI or bypass)MIF IgG ≥ 16302Azithromycin, 500 mg/day × 3 days, 500 mg/wk × 3 moRecurrent CVD14.6% vs 16.4% (P = 0.74) at 24 mo
WIZARD (28)History of MIMIF IgG ≥ 167,000Azithromycin, 600 mg qid × 3 days, 600 mg/wk × 11 wkDeath, MI, unstable angina, repeat bypassOngoing
ACES (60)CADNone4,000Azithromycin, 600 mg/wk × 1 yrAny cardiac eventOngoing
MARBLE (45)CAD, waiting for bypassNone1300Azithromycin, 600 mg/wk × 3 moAny cardiac eventOngoing
STAMINA (45)Acute coronary syndromeSeropositive for C. pneumoniae and H. pylori600Azithromycin or amoxicillin, dose not specifiedEffect on inflammatory markers, any cardiac eventOngoing
  • a bid, twice a day; qid, four times a day.